K. Yitzhak1*, B. Venkata Ramana2, Venugopalaiah P1, E. Vamsi Krishna2
1Ratnam Institute of Pharmacy, Pidathapolur, Muthukur (M), Nellore, Andhra Pradesh, India-524346
2Sasthra college of Pharmaceutica l and Educational Research, Nellore, Andhra Pradesh, India-524346
A B S T R A C T
Migraine is a syndrome that affects a significant fraction of the world population, with a higher prevalence in women (15%) than in men (6%). Approximately 70% of patients have a first-degree relative with a history of migraine. Migraine occurs with increased frequency in patients with mitochondrial disorders, such as Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke like Episodes. Based on the clinical features of migraine, three distinct phases can be discerned: an initiating trigger, an aura and, finally, the headache. . Migraine headache is believed to be the result of abnormal activity in the brain that leads to dilation of the blood vessels on the surface of the brain as well as the tissues that surround the brain. 5-HT synthesis occurs in the entero chromaffin cells; it is then taken up, stored in and released by platelets. In the CNS, 5-HT is synthesized in neurons and is released as a NT. A local vasodilatation of the intracranial extracerebral blood vessels / meningeal blood vessel promoted by specific triggers, potassium channel gene KCNN3 my thus be of pathophysiological importance in migraine (with and without aura) and in the near future migraine treatments.
Keywords: KCNN3, CNS, 5-HT, Encephalopathy, Lactic Acidosis